The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Zai Lab Limited ADR’s stock clocked out at $37.22, down -8.39% from its previous closing price of $40.63. In other words, the price has decreased by -$8.39 from its previous closing price. On the day, 1.07 million shares were traded.
Ratios:
To gain a deeper understanding of ZLAB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.09 and its Current Ratio is at 3.26. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $55.
On March 03, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $29 to $36.10.
On December 14, 2023, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $47.50.Morgan Stanley initiated its Overweight rating on December 14, 2023, with a $47.50 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 02 ’25 when Chen Yajing sold 9,618 shares for $30.00 per share. The transaction valued at 288,540 led to the insider holds 17,429 shares of the business.
Chen Yajing bought 9,618 shares of ZLAB for $288,540 on Jun 02 ’25. On May 13 ’25, another insider, Du Ying, who serves as the Chairperson & CEO of the company, sold 50,000 shares for $28.57 each. As a result, the insider received 1,428,650 and left with 479,851 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.77 while its Price-to-Book (P/B) ratio in mrq is 4.98.
Stock Price History:
Over the past 52 weeks, ZLAB has reached a high of $44.34, while it has fallen to a 52-week low of $16.01. The 50-Day Moving Average of the stock is 15.71%, while the 200-Day Moving Average is calculated to be 27.63%.
Shares Statistics:
A total of 108.42M shares are outstanding, with a floating share count of 108.40M. Insiders hold about 1.31% of the company’s shares, while institutions hold 50.87% stake in the company.
Earnings Estimates
The current rating of Zai Lab Limited ADR (ZLAB) is the result of assessments by 6.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.13 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$0.82 and -$1.75 for the fiscal current year, implying an average EPS of -$1.41. EPS for the following year is $0.14, with 10.0 analysts recommending between $1.38 and -$0.97.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $126.91M. It ranges from a high estimate of $132.31M to a low estimate of $113.8M. As of the current estimate, Zai Lab Limited ADR’s year-ago sales were $100.5MFor the next quarter, 7 analysts are estimating revenue of $153.18M. There is a high estimate of $157.9M for the next quarter, whereas the lowest estimate is $148M.
A total of 16 analysts have provided revenue estimates for ZLAB’s current fiscal year. The highest revenue estimate was $591.32M, while the lowest revenue estimate was $551M, resulting in an average revenue estimate of $567.72M. In the same quarter a year ago, actual revenue was $398.99MBased on 15 analysts’ estimates, the company’s revenue will be $846.88M in the next fiscal year. The high estimate is $962M and the low estimate is $715M.
